Tabla 2. Distribución de patrones de remodelado ventricular según sexo.

Fuente: Historias clínicas

Tabla 3. Distribución de remodelado ventricular según tiempo de evolución de la hipertensión arterial (HTA).

Fuente: Historia clínica.

Tabla 4. Distribución de patrones de remodelado ventricular según grado de control de la hipertensión arterial (HTA).

Fuente: Historia Clínica.

Bibliografía.

1. Sellen C. Hipertensión Arterial: Guía para la prevención, diagnóstico y tratamiento. La Habana: Editorial de Ciencias Médicas, 2008.
2. Armas, N. Armas R; Dueñas H, A; Noval G, R; Castillo G,A; Suárez M,R; Varona P,P Bonet G,M. Enfermedades del corazón y sus características epidemiológicas en la población cubana de 15 años y más. Rev Cubana Invest Bioméd v.28 (4) Ciudad de la Habana oct.-dic. 2009
3. Mathew J, Sleight P, Lonn E. For the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor Ramipril. Circulation 2009;104:1615-21.
4. Bonet M. Prevalencia de Hipertensión Arterial por Provincias. Resultados de la II Encuesta de Nacional de Factores de Riesgo. INHEM. MINSAP 2001.
5. Feldman RD, Zou G, Feagen BG, et al; the STITCH Investigators. The Simplified treatment Intervention to Control Hypertension (STITCH) trial: A cluster randomized controlled trial of a step-care algorithm using initial fixed dose combination therapy for the management of hypertension. Presented at Scientific Sessions 2007 of the American Heart Association meeting; November 4-7, 2007; Orlando, Florida
6. Eugenio N,J, Fernández-Britto R, J. Castillo H, J. Senra A. J. Gutiérrez R,A. Pérez Y,M. Rodríguez A,L..Rodríguez R. Prevalencia y formas de insuficiencia cardíaca en mayores de 65 años. Rev Cubana Invest Biomed 2007;26(2):
7. Engelfriet, M,P; Hoogenveen R, T; Boshuizen H C; van Baal, Pieter H.M. If Heart Failure Underrepresented in National Mortality Statistics?. Eur J Heart Fail. 2011;13(4):377-383
8. Ghali JK, Liao Y, Copper RS. Influence of Left Ventricular Geometric Patterns on prognosis in patiens with or without Coronary artery disease Am Coll Cardiol.1998; 31(1)635-40.
9. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009;119:e391-e479
10. Okin PM, Devereux RB, Jem S. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The LIFE study investigators. Hypertension 2000;36 (5):766-73
11. Morales OJ; Estan Y,,l; Conceptos nuevos sobre el sistema renina angiotensina. Hipertens riesgovasc.2010;27(5):211–217.
12. Fyhquist F, Saijonmaa O, Renin-angiotensin revisited. J Intern Med. 2008;234:224-36.
13. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and celular rsponses to renin. J Clin Invest 2008; 86:643-6.
14. Kumar R, Singh VP, Baker KM. The intracelluular renin-angiotensin system: anew paradigm. Trends Endocrinol Metab.2007;18:208-14.
15. Goikoetxea MJ, Beaumont J, González A, López B, Querejeta R, Larman M, et al. Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovasc Res. 2006; 69:899-907.
16. Varagic.J; Ahmad,S; K. Brosnihan,B; Groban.L; Chappell,MC; E Tallant.EA; et al. Decreased Cardiac Ang-(1–7) is Associated with Salt-induced Cardiac Remodeling and Dysfunction. Ther Adv Cardiovasc Dis. 2010;4(1):17-25
17. Gallagher, P.E., Ferrario, C.M. and Tallant, E.A. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiology. 2008; 295: H2373–H2379.
18. Groban, L., Yamaleyeva, L.M., Westwood, B.M., Houle, T.T., Lin, M., Kitzman, D.W. et al. Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci.2008; 63: 3–11.
19. Grobe, J.L., Mecca, A.P., Lingis, M., Shenoy, V., Bolton, T.A., Machado, J.M. et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol.2007;292: H736–H742.
20. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms of heart failure. Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48: A56-66.
21. Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signalling in physiological control and disease. Crit Rev Eukaryot Gene Expr. 2006;16:1-22.
22. Chobanian AV, Bakris GL, Black HR. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-1252
23. Tang WHW, Francis GS, Morrow D. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116:e99-e109.
24. Krantz MJ, Tanner J, Horwich TB. Influence of hospital length of stay for heart failure on quality of care. Am J Cardiol. 2008;102:1693-1697.
25. Devereaux RD, Reickek N. Echocardiographic determination of left ventricular mass in man. Circulation 1997; 55:613-8.
26. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL. Report of the American Society of Echocardiography Committee in nomenclature and standards in two dimensional echocardiography. Circulation. 1980;62:212-7.